DoW Peer Reviewed Cancer, Clinical Trial Award
Funds cancer clinical trials from first-in-human through phase III, with regulatory filings already due at the application deadline.
A treatment idea that has cleared the lab still has to prove itself in people, and the biggest single mechanism in this programme's cancer portfolio exists to move that step along fast.
The award funds clinical trials with real potential to change how cancer is treated or managed, inside at least one of the programme's FY26 Topic Areas. What counts as a trial here is broad — new products, drugs o…
Clinical trials of new products, pharmacologic agents, devices, clinical guidance or emerging technologies for cancer treatment or management, within at least one FY26 PRCRP Topic Area, ranging from small proof-of-concept studies to large phase III trials. A clinical trial is required; a specific regulatory filing (IND, IDE or equivalent) must already be submitted by the application deadline where one applies. Patient advocates are required and animal studies are not allowed.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up